4 262

Cited 0 times in

The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.

Authors
 Han Sang Kim  ;  Hye Ryun Kim  ;  Gun Min Kim  ;  Hyo Song Kim  ;  Yoon Woo Koh  ;  Se Hun Kim  ;  Eun Chang Choi  ;  Yun Kyoung Hong  ;  Ji Hee Sung  ;  Sun Mi Kim  ;  Joo Hang Kim  ;  Byoung Chul Cho 
Citation
 CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.70(4) : 539-546, 2012 
Journal Title
 CANCER CHEMOTHERAPY AND PHARMACOLOGY 
ISSN
 0344-5704 
Issue Date
2012
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Carcinoma, Squamous Cell/drug therapy* ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/pathology ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Drug Combinations ; Female ; Head and Neck Neoplasms/drug therapy* ; Head and Neck Neoplasms/mortality ; Head and Neck Neoplasms/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Oxonic Acid/administration & dosage* ; Oxonic Acid/adverse effects ; Tegafur/administration & dosage* ; Tegafur/adverse effects
Keywords
Head and neck cancer ; S-1 ; Cisplatin ; Recurrent ; Metastatic
Abstract
PURPOSE: To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. METHODS: A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m(2) on days 1-14 and with cisplatin 70 mg/m(2) on day 1 every 3 weeks for a maximum of six cycles as a first-line palliative chemotherapy. Patients who achieved complete response (CR), partial response (PR) or stable disease (SD) after six cycles received S-1 monotherapy as a maintenance therapy. RESULTS: The median patient age was 55 years (range 33-79), 89.8 % were male, and the Eastern Cooperative Oncology Group performance status distribution was 0/1/2 (20.4 %/73.5 %/6.1 %). Of the 43 evaluable patients, 2 (4.1 %) achieved CR and 20 (40.8 %) had a PR, for an overall response rate of 44.9 %. Thirteen patients (26.6 %) had SD. The median number of chemotherapy treatments was 4 (range 1-18). Nine patients received maintenance S-1 monotherapy after six cycles of combination chemotherapy. With a mean 10.5 months (range 1.3-25.1) of follow-up, the median progression-free and overall survival were 4.5 (95 % CI, 3.7-5.3 months) and 10.8 months (95 % CI, 5.9-15.6 months), respectively. The main grade 3-4 toxicities were neutropenia (37 %), anemia (16 %) and general weakness (8 %). Other toxicities, including nausea/vomiting, mucositis and neuropathy, were mostly grade 1-2 and easily manageable. CONCLUSIONS: The combination of S-1/cisplatin therapy had a favorable efficacy with manageable toxicity as a first-line chemotherapy regimen for advanced head and neck squamous cell carcinoma patients.
Full Text
http://link.springer.com/article/10.1007%2Fs00280-012-1933-8
DOI
22868340
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers
Yonsei Authors
Kho, Yoon Woo(고윤우)
Kim, Gun Min(김건민) ORCID logo https://orcid.org/0000-0001-9167-8682
Kim, Sun Mi(김선미)
Kim, Se Heon(김세헌)
Kim, Joo Hang(김주항)
Kim, Han Sang(김한상) ORCID logo https://orcid.org/0000-0002-6504-9927
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Choi, Eun Chang(최은창)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/89863
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse